LISCure Biosciences, a South Korea-based clinical-stage biopharmaceutical company, announced on Friday that it has received Fast Track designation from the US Food and Drug Administration (FDA) for LB-P8, its investigational drug for the treatment of primary sclerosing cholangitis (PSC).
PSC is a rare, chronic, cholestatic liver disease with significant unmet medical needs as there are no approved drugs available to treat it.
LB-P8 is undergoing assessment in a Phase 2 study in patients with PSC. According to LISCure, it is the only live biotherapeutic product currently reported to be in clinical development to address the requirement of individuals with PSC.
The company is carrying out a Phase 2 study in multiple sites across the US and Europe. Preliminary results are expected to be revealed in early 2025. Based on the results, the company says that it will make maximum use of accelerated programmes to bring LB-P8 to market as quickly as possible.
LB-P8 is also being developed for metabolic dysfunction-associated steatohepatitis (MASH).
Pierre Fabre Pharmaceuticals reports FDA acceptance and Priority Review of Tabelecleucel BLA
Bavarian Nordic's chikungunya vaccine receives validation from EMA for accelerated review
Atara Biotherapeutics gains FDA Priority Review for tabelecleucel
Hyperfine secures FDA clearance for faster brain imaging software
Silo Pharma agrees Alzheimer's drug licence
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation
Camurus reports positive Phase 3 ACROINNOVA 2 results
Acurx Pharmaceuticals presents positive Ibezapolstat Phase 2 clinical trial results for CDI